LTI
RCUS icon

Laffer Tengler Investments’s Arcus Biosciences RCUS Stock Holding History

Laffer Tengler Investments’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-180
Closed -$3.72K – 437
2022
Q4 		$3.72K Buy
+180
New +$4.95K ﹤0.01% 397

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Laffer Tengler Investments's RCUS Position: Q1 2023 in Review

Laffer Tengler Investments sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 180 shares — an estimated $3.72K sold.

Laffer Tengler Investments first reported a position in RCUS in Q4 2022 and held it in 1 quarter. The position peaked at $3.72K in Q4 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • Laffer Tengler Investments reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
  • Laffer Tengler Investments sold 180 Arcus Biosciences shares in Q1 2023, an estimated $3.72K.
  • Laffer Tengler Investments first reported a position in Arcus Biosciences in Q4 2022 and held it in 1 quarter.
  • Laffer Tengler Investments's Arcus Biosciences position peaked at $3.72K in Q4 2022.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on Laffer Tengler Investments's 13F filing for Q1 2023, filed 9 May 2023.